55
Views
0
CrossRef citations to date
0
Altmetric
Review

Erectile and Sexual Dysfunction in the Aging Diabetic Male

, &
Pages 1025-1034 | Published online: 14 Dec 2006

Bibliography

  • Feldman HA , GoldsteinI, HatzichristouDG, KraneRJ, McKinlayJB: Impotence and its medical and psychosocial correlates: results of the Massachusetts Male Aging Study.J. Urol.151(1), 54–61(1994).
  • Braun M , WassmerG, KlotzTet al.: Epidemiology of erectile dysfunction: results of the ‘Cologne Male Survey’. Int. J. Impot. Res.12(6), 305–311(2000).
  • Rosen R , AltweinJ, BoylePet al.: Lower urinary tract symptoms and male sexual dysfunction: the multinational survey of the aging male (MSAM-7). Eur. Urol.44(6), 637–649(2003).
  • Nicolosi A , LaumannEO, GlasserDBet al.: Sexual behavior and sexual dysfunctions after age 40: the global study of sexual attitudes and behaviors. Urology64(5), 991–997(2004).
  • Araujo AB , MohrBA, McKinlayJB: Changes in sexual function in middle-aged and older men: longitudinal data from the Massachusetts Male Aging Study.J. Am. Geriatr. Soc.52(9), 1502–1509(2004).
  • Christ GJ , MaayaniS, ValcicM, MelmanA: Pharmacological studies of human erectile tissue: characteristics of spontaneous contractions and alterations in α-adrenoceptor responsiveness with age and disease in isolated tissues.Br. J. Pharmacol.101(2), 375–381(1990).
  • Kaiser FE , VioscaSP, MorleyJEet al.: Impotence and aging: clinical and hormonal factors. J. Am. Geriatr. Soc.36(6), 511–519(1988).
  • Rowland DL , GreenleafW, MasM, Myers L, Davidson JM: Penile and finger sensory thresholds in young, aging, and diabetic males. Arch. Sex Behav.18(1), 1–12(1989).
  • Corona G , MannucciE, MansaniRet al.: Aging and pathogenesis of erectile dysfunction. Int. J. Impot. Res.16(5), 395–402(2004).
  • Rosen MP , GreenfieldAJ, WalkerTGet al.: Cigarette smoking: an independent risk factor for atherosclerosis in the hypogastric-cavernous arterial bed of men with arteriogenic impotence. J. Urol.145(4), 759–763(1991).
  • Rajfer J , RosciszewskiA, MehringerM: Prevalence of corporeal venous leakage in impotent men.J. Urol.140(1), 69–71(1988).
  • Shiri R , KoskimakiJ, HakkinenJet al.: Cardiovascular drug use and the incidence of erectile dysfunction. Int. J. Impot. Res. DOI 10.1038/sj.ijir.3901516 (2006) (Epub ahead of print).
  • Grimm RH Jr, Grandits GA, Prineas RJ et al.: Long-term effects on sexual function of five antihypertensive drugs and nutritional hygienic treatment in hypertensive men and women. Treatment of Mild Hypertension Study (TOMHS). Hypertension29(1 Pt 1), 8–14(1997).
  • Papatsoris AG , KorantzopoulosPG: Hypertension, antihypertensive therapy, and erectile dysfunction.Angiology57(1), 47–52(2006).
  • Horowitz JD , GobleAJ: Drugs and impaired male sexual function.Drugs18(3), 206–217(1979).
  • Chang SW , FineR, SiegelDet al.: The impact of diuretic therapy on reported sexual function. Arch. Intern. Med.151(12), 2402–2408(1991).
  • Wolfe MM : Impotence on cimetidine treatment.N. Engl. J. Med.300(2), 94 (1979).
  • Shabsigh R , KleinLT, SeidmanSet al.: Increased incidence of depressive symptoms in men with erectile dysfunction. Urology52(5), 848–852(1998).
  • Araujo AB , DuranteR, FeldmanHA, GoldsteinI, McKinlayJB: The relationship between depressive symptoms and male erectile dysfunction: cross-sectional results from the Massachusetts Male Aging Study.Psychosom. Med.60(4), 458–465(1998).
  • Vermeulen A : Andropause.Maturitas34(1), 5–15(2000).
  • Tenover JS : Declining testicular function in aging men.Int. J. Impot. Res.15(Suppl.) 4S3–4S8 (2003).
  • Angulo J , CuevasP, GabanchoSet al.: Enhancement of both EDHF and NO/cGMP pathways is necessary to reverse erectile dysfunction in diabetic rats. J. Sex. Med.2(3), 341–346(2005).
  • Bancroft J , WuFC: Changes in erectile responsiveness during androgen replacement therapy.Arch. Sex Behav.12(1), 59–66(1983).
  • Juenemann KP , LueTF, LuoJAet al.: The effect of cigarette smoking on penile erection. J. Urol.138(2), 438–441(1987).
  • Miller NS , GoldMS: The human sexual response and alcohol and drugs.J. Subst. Abuse Treat.5(3), 171–177(1988).
  • Sun P , CameronA, SeftelAet al.: Erectile dysfunction – an observable marker of diabetes mellitus? A large national epidemiological study. J. Urol.176(3), 1081–1085(2006).
  • Maatman TJ , MontagueDK, MartinLM: Erectile dysfunction in men with diabetes mellitus.Urology29(6), 589–592(1987).
  • Deutsch S , ShermanL: Previously unrecognized diabetes mellitus in sexually impotent men.JAMA244(21), 2430–2432(1980).
  • Berardinucci D , MoralesA, HeatonJP, FenemoreJ, BloomS: Surgical treatment of penile veno-occlusive dysfunction: is it justified?Urology47(1), 88–92(1996).
  • Sarramon JP , BertrandN, MalavaudB, RischmannP: Microrevascularisation of the penis in vascular impotence.Int. J. Impot. Res.9(3), 127–133(1997).
  • Manning M , JunemannKP, ScheepeJRet al.: Long-term followup and selection criteria for penile revascularization in erectile failure. J. Urol.160(5), 1680–1684(1998).
  • Schultheiss D , TrussMC, BeckerAJ, Stief CG, Jonas U: Long-term results following dorsal penile vein ligation in 126 patients with veno-occlusive dysfunction. Int. J. Impot. Res.9(4), 205–209(1997).
  • Desai KM , DembnyK, MorganH, Gingell JC, Prothero D: Neurophysiological investigation of diabetic impotence. Are sacral response studies of value? Br. J. Urol.61(1), 68–73(1988).
  • Kaneko S , BradleyWE: Penile electrodiagnosis. Value of bulbocavernosus reflex latency versus nerve conduction velocity of the dorsal nerve of the penis in diagnosis of diabetic impotence.J. Urol.137(5), 933–935(1987).
  • Parazzini F , Menchini Fabris F, Bortolotti A et al.: Frequency and determinants of erectile dysfunction in Italy. Eur. Urol.37(1), 43–49(2000).
  • Fedele D , CoscelliC, SanteusanioFet al.: Erectile dysfunction in diabetic subjects in Italy. Gruppo Italiano Studio Deficit Erettile nei Diabetici. Diabetes Care21(11), 1973–1977(1998).
  • Fedele D , BortolottiA, CoscelliCet al.: Erectile dysfunction in Type 1 and Type 2 diabetics in Italy. On behalf of Gruppo Italiano Studio Deficit Erettile nei Diabetici. Int. J. Epidemiol.29(3), 524–531(2000).
  • McCulloch DK , YoungRJ, PrescottRJ, CampbellIW, ClarkeBF: The natural history of impotence in diabetic men.Diabetologia26(6), 437–440(1984).
  • Herman A , AdarR, RubinsteinZ: Vascular lesions associated with impotence in diabetic and nondiabetic arterial occlusive disease.Diabetes27(10), 975–981(1978).
  • Wang CJ , ShenSY, WuCC, HuangCH, ChiangCP: Penile blood flow study in diabetic impotence.Urol. Int.50(4), 209–212(1993).
  • Morano S : Pathophysiology of diabetic sexual dysfunction.J. Endocrinol. Invest.26(3 Suppl), 65–69(2003).
  • Italiano G , PetrelliL, MarinAet al.: Ultrastructural analysis of the cavernous and dorsal penile nerves in experimental diabetes. Int. J. Impot. Res.5(3), 149–160(1993).
  • Faerman I , GlocerL, FoxD, JadzinskyMN, RapaportM: Impotence and diabetes. Histological studies of the autonomic nervous fibers of the corpora cavernosa in impotent diabetic males.Diabetes23(12), 971–976(1974).
  • Vernet D , CaiL, GarbanHet al.: Reduction of penile nitric oxide synthase in diabetic BB/WORdp (Type I) and BBZ/WORdp (type II) rats with erectile dysfunction. Endocrinology136(12), 5709–5717(1995).
  • Ehmke H , JunemannKP, MayerB, KummerW: Nitric oxide synthase and vasoactive intestinal polypeptide colocalization in neurons innervating the human penile circulation.Int. J. Impot. Res.7(3), 147–156(1995).
  • Seftel AD , VaziriND, NiZet al.: Advanced glycation end products in human penis: elevation in diabetic tissue, site of deposition, and possible effect through iNOS or eNOS. Urology50(6), 1016–1026(1997).
  • Angulo J , CuevasP, FernandezAet al.: Diabetes impairs endothelium-dependent relaxation of human penile vascular tissues mediated by NO and EDHF. Biochem. Biophys. Res. Commun.312(4), 1202–1208(2003).
  • Cartledge JJ , EardleyI, MorrisonJF: Advanced glycation end-products are responsible for the impairment of corpus cavernosal smooth muscle relaxation seen in diabetes.BJU Int.87(4), 402–407(2001).
  • Saenz de Tejada I , GoldsteinI, AzadzoiK, KraneRJ, CohenRA: Impaired neurogenic and endothelium-mediated relaxation of penile smooth muscle from diabetic men with impotence.N. Engl. J. Med.320(16), 1025–1030(1989).
  • Murray FT , WyssHU, ThomasRG, SpevackM, GlarosAG: Gonadal dysfunction in diabetic men with organic impotence.J. Clin. Endocrinol. Metab.65(1), 127–135(1987).
  • Murray FT , JohnsonRD, SciadiniMet al.: Erectile and copulatory dysfunction in chronically diabetic BB/WOR rats. Am. J. Physiol.263(1 Pt 1), E151–E157 (1992).
  • Nakanishi S , YamaneK, KameiN, Okubo M, Kohno N: Erectile dysfunction is strongly linked with decreased libido in diabetic men. Aging Male7(2), 113–119(2004).
  • Salonia A , BrigantiA, MontorsiPet al.: Safety and tolerability of oral erectile dysfunction treatments in the elderly. Drugs Aging22(4), 323–338(2005).
  • Fujisawa M , SawadaK: Clinical efficacy and safety of sildenafil in elderly patients with erectile dysfunction.Arch. Androl.50(4), 255–260(2004).
  • Goldstein I , LueTF, Padma-NathanHet al.: Oral sildenafil in the treatment of erectile dysfunction. 1998. J. Urol.167(2 Pt 2), 1197–1204(2002).
  • Rendell MS , RajferJ, WickerPA, Smith MD: Sildenafil for treatment of erectile dysfunction in men with diabetes: a randomized controlled trial. Sildenafil Diabetes Study Group. JAMA281(5), 421–426(1999).
  • Park K , KuJH, KimSW, PaickJS: Risk factors in predicting a poor response to sildenafil citrate in elderly men with erectile dysfunction.BJU Int.95(3), 366–370(2005).
  • Stuckey BG , JadzinskyMN, MurphyLJet al.: Sildenafil citrate for treatment of erectile dysfunction in men with Type 1 diabetes: results of a randomized controlled trial. Diabetes Care26(2), 279–284(2003).
  • Goldstein I , YoungJM, FischerJet al.: Vardenafil, a new phosphodiesterase type 5 inhibitor, in the treatment of erectile dysfunction in men with diabetes: a multicenter double-blind placebo-controlled fixed-dose study. Diabetes Care26(3), 777–783(2003).
  • Saenz de Tejada I , AnglinG, KnightJR, EmmickJT: Effects of tadalafil on erectile dysfunction in men with diabetes.Diabetes Care25(12), 2159–2164(2002).
  • Behrend L , Vibe-PetersenJ, PerrildH: Sildenafil in the treatment of erectile dysfunction in men with diabetes: demand, efficacy and patient satisfaction.Int. J. Impot. Res.17(3), 264–269(2005).
  • Wagner G , MontorsiF, AuerbachS, Collins M: Sildenafil citrate (VIAGRA) improves erectile function in elderly patients with erectile dysfunction: a subgroup analysis. J. Gerontol. A. Biol. Sci. Med. Sci.56(2), M113–M119 (2001).
  • Linet OI , NeffLL: Intracavernous prostaglandin E1 in erectile dysfunction.Clin. Investig.72(2), 139–149(1994).
  • Porst H : The rationale for prostaglandin E1 in erectile failure: a survey of worldwide experience.J. Urol.155(3), 802–815(1996).
  • Chew KK , StuckeyBG: Clinical course of penile fibrosis in intracavernosal prostaglandin E1 injection therapy: a follow-up of 44 patients.Int. J. Impot. Res.15(2), 94–98(2003).
  • Canale D , GiorgiPM, LencioniRet al.: Long-term intracavernous self-injection with prostaglandin E1 for the treatment of erectile dysfunction. Int. J. Androl.19(1), 28–32(1996).
  • Bennett AH , CarpenterAJ, BaradaJH: An improved vasoactive drug combination for a pharmacological erection program.J. Urol.146(6), 1564–1565(1991).
  • Heaton JP , LordingD, LiuSNet al.: Intracavernosal alprostadil is effective for the treatment of erectile dysfunction in diabetic men. Int. J. Impot. Res.13(6), 317–321(2001).
  • Perimenis P , KonstantinopoulosA, Perimeni PP et al.: Long-term treatment with intracavernosal injections in diabetic men with erectile dysfunction. Asian J. Androl.8(2), 219–224(2006).
  • Ryder RE , CloseCF, MoriartyKT, Moore KT, Hardisty CA: Impotence in diabetes: aetiology, implications for treatment and preferred vacuum device. Diabet. Med.9(10), 893–898(1992).
  • Padma-Nathan H , HellstromWJ, KaiserFEet al.: Treatment of men with erectile dysfunction with transurethral alprostadil. Medicated Urethral System for Erection (MUSE) Study Group. N. Engl. J. Med.336(1), 1–7(1997).
  • Williams G , AbbouCC, AmarETet al.: Efficacy and safety of transurethral alprostadil therapy in men with erectile dysfunction. MUSE Study Group. Br. J. Urol.81(6), 889–894(1998).
  • Lewis RW : Transurethral alprostadil with MUSE (medicated urethral system for erection) vs intracavernous alprostadil – a comparative study in 103 patients with erectile dysfunction.Int. J. Impot. Res.10(1), 61–62(1998).
  • Ekman P , SjogrenL, EnglundG, Persson BE: Optimizing the therapeutic approach of transurethral alprostadil. BJU Int.86(1), 68–74(2000).
  • Akoz T , KargiE, KapucuMR, ErdoganB: The use of iliac bone flap as a penile stiffener in a diabetic patient with erectile dysfunction.Plast. Reconstr. Surg.103(7), 1975–1978(1999).
  • Mulcahy JJ , AustoniE, BaradaJHet al.: The penile implant for erectile dysfunction. J. Sex. Med.1(1), 98–109(2004).
  • Levine LA , EstradaCR, MorgentalerA: Mechanical reliability and safety of, and patient satisfaction with the Ambicor inflatable penile prosthesis: results of a 2 center study.J. Urol.166(3), 932–937(2001).
  • Montorsi F , RigattiP, CarmignaniGet al.: AMS three-piece inflatable implants for erectile dysfunction: a long-term multi-institutional study in 200 consecutive patients. Eur. Urol.37(1), 50–55(2000).
  • Bishop JR , MoulJW, SihelnikSAet al.: Use of glycosylated hemoglobin to identify diabetics at high risk for penile periprosthetic infections. J. Urol.147(2), 386–388(1992).
  • Wilson SK , CarsonCC, ClevesMA, Delk JR 2nd: Quantifying risk of penile prosthesis infection with elevated glycosylated hemoglobin. J. Urol.159(5), 1537–1540(1998).
  • Cakan M , DemirelF, KarabacakO, YalcinkayaF, AltugU: Risk factors for penile prosthetic infection.Int. Urol. Nephrol.35(2), 209–213(2003).
  • Bejany DE , PeritoPE, LustgartenM, RhamyRK: Gangrene of the penis after implantation of penile prosthesis: case reports, treatment recommendations and review of the literature.J. Urol.150(1), 190–192(1993).
  • Gerig NE , MeachamRB, OhlDA: Use of electroejaculation in the treatment of ejaculatory failure secondary to diabetes mellitus.Urology49(2), 239–242(1997).
  • Kamischke A , NieschlagE: Update on medical treatment of ejaculatory disorders.Int. J. Androl.25(6), 333–344(2002).
  • Tomasi PA , FanciulliG, DelitalaG: Successful treatment of retrograde ejaculation with the α1-adrenergic agonist methoxamine: case study.Int. J. Impot. Res.17(3), 297–299(2005).
  • Jannini EA , LenziA: Epidemiology of premature ejaculation.Curr. Opin. Urol.15(6), 399–403(2005).
  • Basile Fasolo C , MironeV, GentileV, ParazziniF, RicciE: Premature ejaculation: prevalence and associated conditions in a sample of 12,558 men attending the andrology prevention week 2001 – a study of the Italian Society of Andrology (SIA).J. Sex. Med.2(3), 376–382(2005).
  • Corona G , PetroneL, MannucciEet al.: Psycho–biological correlates of rapid ejaculation in patients attending an andrologic unit for sexual dysfunctions. Eur. Urol.46(5), 615–622(2004).
  • El-Sakka AI : Premature ejaculation in non-insulin-dependent diabetic patients.Int. J. Androl.26(6), 329–334(2003).
  • Jannini EA , LombardoF, LenziA: Correlation between ejaculatory and erectile dysfunction.Int. J. Androl.28(Suppl.) 240–245(2005).
  • Wylie KR , RalphD: Premature ejaculation: the current literature.Curr. Opin. Urol.15(6), 393–398(2005).
  • Usta MF , KendirciM, GurSet al.: The breakdown of preformed advanced glycation end products reverses erectile dysfunction in streptozotocin-induced diabetic rats: preventive versus curative treatment. J. Sex. Med.3(2), 242–252(2006).
  • Gholami SS , RogersR, ChangJet al.: The effect of vascular endothelial growth factor and adeno-associated virus mediated brain derived neurotrophic factor on neurogenic and vasculogenic erectile dysfunction induced by hyperlipidemia. J. Urol.169(4), 1577–1581(2003).
  • Wessells H , TealTH, LuttrellIP, Sullivan CJ: Effect of endothelial cell-based iNOS gene transfer on cavernosal eNOS expression and mouse erectile responses. Int. J. Impot. Res. (2006).
  • Cross WR , ThomasDF, SouthgateJ: Tissue engineering and stem cell research in urology.BJU Int.92(2), 165–171(2003).
  • Bochinski D , LinGT, NunesLet al.: The effect of neural embryonic stem cell therapy in a rat model of cavernosal nerve injury. BJU Int.94(6), 904–909(2004).
  • Yoo JJ , ParkHJ, AtalaA: Tissue-engineering applications for phallic reconstruction.World J. Urol.18(1), 62–66(2000).
  • Kwon TG , YooJJ, AtalaA: Autologous penile corpora cavernosa replacement using tissue engineering techniques.J. Urol.168(4 Pt 2), 1754–1758(2002).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.